398 related articles for article (PubMed ID: 26603347)
41. Microneedle patch delivery to the skin of virus-like particles containing heterologous M2e extracellular domains of influenza virus induces broad heterosubtypic cross-protection.
Kim MC; Lee JW; Choi HJ; Lee YN; Hwang HS; Lee J; Kim C; Lee JS; Montemagno C; Prausnitz MR; Kang SM
J Control Release; 2015 Jul; 210():208-16. PubMed ID: 26003039
[TBL] [Abstract][Full Text] [Related]
42. Precise microinjection into skin using hollow microneedles.
Wang PM; Cornwell M; Hill J; Prausnitz MR
J Invest Dermatol; 2006 May; 126(5):1080-7. PubMed ID: 16484988
[TBL] [Abstract][Full Text] [Related]
43. Cutaneous vaccination: antigen delivery into or onto the skin.
Weniger BG; Glenn GM
Vaccine; 2013 Jul; 31(34):3389-91. PubMed ID: 23684830
[No Abstract] [Full Text] [Related]
44. Vaccines, our shared responsibility.
Pagliusi S; Jain R; Suri RK;
Vaccine; 2015 May; 33(19):2197-2202. PubMed ID: 25749248
[TBL] [Abstract][Full Text] [Related]
45. Transdermal drug delivery systems for fighting common viral infectious diseases.
Wang FY; Chen Y; Huang YY; Cheng CM
Drug Deliv Transl Res; 2021 Aug; 11(4):1498-1508. PubMed ID: 34024014
[TBL] [Abstract][Full Text] [Related]
46. Dissolvable microneedle patches for the delivery of cell-culture-derived influenza vaccine antigens.
Kommareddy S; Baudner BC; Oh S; Kwon SY; Singh M; O'Hagan DT
J Pharm Sci; 2012 Mar; 101(3):1021-7. PubMed ID: 22190403
[TBL] [Abstract][Full Text] [Related]
47. Vaccine preventable diseases and vaccination coverage in Aboriginal and Torres Strait Islander people, Australia 2003 to 2006.
Menzies R; Turnour C; Chiu C; McIntyre P
Commun Dis Intell Q Rep; 2008 Jun; 32 Suppl():S2-67. PubMed ID: 18711998
[TBL] [Abstract][Full Text] [Related]
48. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults.
Van Damme P; Oosterhuis-Kafeja F; Van der Wielen M; Almagor Y; Sharon O; Levin Y
Vaccine; 2009 Jan; 27(3):454-9. PubMed ID: 19022318
[TBL] [Abstract][Full Text] [Related]
49. The potential role of using vaccine patches to induce immunity: platform and pathways to innovation and commercialization.
Badizadegan K; Goodson JL; Rota PA; Thompson KM
Expert Rev Vaccines; 2020 Feb; 19(2):175-194. PubMed ID: 32182145
[No Abstract] [Full Text] [Related]
50. Induction of broad immunity by thermostabilised vaccines incorporated in dissolvable microneedles using novel fabrication methods.
Vrdoljak A; Allen EA; Ferrara F; Temperton NJ; Crean AM; Moore AC
J Control Release; 2016 Mar; 225():192-204. PubMed ID: 26774221
[TBL] [Abstract][Full Text] [Related]
51. [Insufficient vaccination is a threat against world health].
Gjersvik PJ
Tidsskr Nor Laegeforen; 2003 Mar; 123(6):831. PubMed ID: 12693127
[No Abstract] [Full Text] [Related]
52. Microneedle applications for DNA vaccine delivery to the skin.
Seok HY; Suh H; Baek S; Kim YC
Methods Mol Biol; 2014; 1143():141-58. PubMed ID: 24715287
[TBL] [Abstract][Full Text] [Related]
53. Microneedle Systems for Vaccine Delivery: the story so far.
Hossain MK; Ahmed T; Bhusal P; Subedi RK; Salahshoori I; Soltani M; Hassanzadeganroudsari M
Expert Rev Vaccines; 2020 Dec; 19(12):1153-1166. PubMed ID: 33427523
[TBL] [Abstract][Full Text] [Related]
54. From the laboratory to the end-user: a primary packaging study for microneedle patches containing amoxicillin sodium.
McAlister E; Kearney MC; Martin EL; Donnelly RF
Drug Deliv Transl Res; 2021 Oct; 11(5):2169-2185. PubMed ID: 33452653
[TBL] [Abstract][Full Text] [Related]
55. DNA vaccination for cervical cancer: Strategic optimisation of RALA mediated gene delivery from a biodegradable microneedle system.
Cole G; Ali AA; McCrudden CM; McBride JW; McCaffrey J; Robson T; Kett VL; Dunne NJ; Donnelly RF; McCarthy HO
Eur J Pharm Biopharm; 2018 Jun; 127():288-297. PubMed ID: 29510205
[TBL] [Abstract][Full Text] [Related]
56. Development of the novel coating formulations for skin vaccination using stainless steel microneedle.
Kim SJ; Shin JH; Noh JY; Song CS; Kim YC
Drug Deliv Transl Res; 2016 Oct; 6(5):486-97. PubMed ID: 27519363
[TBL] [Abstract][Full Text] [Related]
57. Safety and efficacy of novel dermal and epidermal microneedle delivery systems for rabies vaccination in healthy adults.
Laurent PE; Bourhy H; Fantino M; Alchas P; Mikszta JA
Vaccine; 2010 Aug; 28(36):5850-6. PubMed ID: 20600481
[TBL] [Abstract][Full Text] [Related]
58. The success of microneedle-mediated vaccine delivery into skin.
Marshall S; Sahm LJ; Moore AC
Hum Vaccin Immunother; 2016 Nov; 12(11):2975-2983. PubMed ID: 27050528
[TBL] [Abstract][Full Text] [Related]
59. Intradermal delivery for vaccine dose sparing: overview of current issues.
Zehrung D; Jarrahian C; Wales A
Vaccine; 2013 Jul; 31(34):3392-5. PubMed ID: 23176978
[TBL] [Abstract][Full Text] [Related]
60. Evaluating new vaccines for developing countries. Efficacy or effectiveness?
Clemens J; Brenner R; Rao M; Tafari N; Lowe C
JAMA; 1996 Feb; 275(5):390-7. PubMed ID: 8569019
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
